Skip to main content


How a drugmaker gamed the system to keep generic competition away

By NPR  
   May 17, 2018

When Celgene Corp. first started marketing the drug Revlimid to treat multiple myeloma in 2006, the price was $6,195 for 21 capsules, a month's supply. By the time David Mitchell started taking Revlimid in November 2010, Celgene had bumped the price up to about $8,000 a month.

Full story

Get the latest on healthcare leadership in your inbox.